Personalized Medicine

The video is loading
POSTED:
May 29, 2012
TAGS:
BY:
Mark R. Green

About This Video

New Realities in Oncology

How personalized medicine impacts the clinical and business sides of oncology today, and predictions for future impact, with Dr. Mark Green (Chief Medical Officer) and Doug Neely (Senior Director) of Xcenda. Watch and listen as we cover key topics including:

  • What pharmaceutical manufacturers need to consider in developing and marketing for a personalized medicine approach
  • Challenges that pharmaceutical manufacturers face in providing access to patients
  • How personally targeted oncological therapies fit in with the overall sequence of cancer therapies

 

Mark R. Green

Mark R. Green

Dr. Mark Green is chief medical officer of Xcenda, where he collaborates with manufacturers to gather strategic insight into how and why medical providers make the choices they do relative to patient treatment. Dr. Green leads the Network for Oncology Communication and Research (NOCR), a nationally represented group of nearly 8,000 academic, hospital, and community-based oncologists and hematologists as well as more than 1,600 mid-level providers and oncology nurses.

Prior to joining Xcenda in 2007, Dr. Green was medical director for the Network for Medical Communication and Research and a clinical professor of medicine at the Medical University of South Carolina. Previously, he held numerous faculty positions at the University of California San Diego School of Medicine.

Dr. Green received his undergraduate and medical degrees from Harvard University and did post-graduate training at the Beth Israel Hospital in Boston, the National Cancer Institute and Stanford University.

Leave a Comment